Neomorph
PrivateLast Round
Series B
Apr 13, 2026
Total Funding Raised
$209M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Neomorph is a biotechnology company that develops molecular glue degraders to target and destroy disease-causing proteins that have historically been considered undruggable.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neomorph Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Neomorph Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 13, 2026 | ||||
| Series A | Dec 22, 2020 | ||||
| Seed | Mar 31, 2020 |
Key People
Founding team and executive leadership
Neomorph Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B, Series A |
| Binney Street Capital | Series B |
| Alexandria Venture Investments | Series B |
| Longwood Fund | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Partnering with the Center for Protein Degradation at Dana-Farber Cancer Institute.
- Apr 14, 2026
NEO-811 therapy details to be presented at AACR Annual Meeting.
Neomorph Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neomorph's valuation, stock price, and market status.